Mitsubishi Tanabe Pharma to Present ND0612 Data at 2024 Parkinson's Congress

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has announced that it will present seven studies on the investigational drug ND0612 at the 2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Philadelphia, Pennsylvania, from September 27 to October 1. ND0612 is being tested as a continuous 24-hour subcutaneous infusion of liquid levodopa/carbidopa for the treatment of Parkinson’s disease (PD).

Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA, expressed enthusiasm about presenting the research findings from their Phase 2 and 3 studies, including one-year outcomes from the open-label extension period of the pivotal Phase 3 BouNDless trial. He noted that these presentations underscore MTPA’s commitment to understanding Parkinson’s disease, which affects nearly one million people in the United States.

The posters will be displayed in Exhibit Hall A on September 29 from 1:00 to 3:00 p.m. ET, covering a variety of data from the BouNDless trial (NCT04006210). This trial evaluates ND0612 in PD patients experiencing motor fluctuations, leveraging patient-reported outcomes to assess quality of life and daily motor experiences. The presentations will also include one-year outcomes from the ongoing open-label extension phase of the BouNDless trial.

Key presentations include:
1. "Quality of Life with 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612): PDQ-39 Results from a Phase 3 Randomized, Active-Controlled Study" (Abstract #: 648).
2. "Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of PD and Experiences of Daily Living" (Abstract #: 685).
3. "Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor State Transitions Throughout the Day" (Abstract #: 683).
4. "Subgroup Analyses of a Phase 3, Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson's Patients" (Abstract #: 666).
5. "Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson's Disease" (Abstract #: 653).

Additional presentations will highlight findings from Phase 2 and Phase 3 studies, exploring treatment outcomes from a 24-hour regimen of ND0612. These include the characterization of adverse events (AEs) such as infusion site reactions and dopaminergic treatment-emergent AEs.

Specific presentations on adverse events include:
1. "Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612" (Abstract #: 665).
2. "Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612" (Abstract #: 684).

MTPA will also host a disease awareness discussion on PD during the Corporate Therapeutic Symposium on September 29 from 1:00 to 2:00 p.m. ET.

ND0612 is an investigational drug-device combination therapy, involving a 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa. This treatment is aimed at managing motor fluctuations in PD patients. The development of ND0612 is led by NeuroDerm, Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC).

Mitsubishi Tanabe Pharma America, Inc., based in Jersey City, New Jersey, is a subsidiary of MTPC. The company focuses on developing and commercializing pharmaceutical products in North America.

Mitsubishi Tanabe Pharma Corporation, headquartered in Osaka, Japan, is one of the world's oldest pharmaceutical companies, founded in 1678. It is part of the Mitsubishi Chemical Group and focuses on areas such as central nervous system disorders, immuno-inflammation, diabetes, kidney diseases, and cancer, emphasizing precision medicine and comprehensive patient care.

NeuroDerm, Ltd., based in Israel, aims to improve the quality of life for patients and their families through innovative drug-device combination therapies. The company focuses on central nervous system product candidates.